MicroRNA-381 serves as a prognostic factor and inhibits migration and invasion in non-small cell lung cancer by targeting LRH-1 Retraction in /10.3892/or.2023.8640

Tian,Chunyan; Li,Jun; Ren,Lili; Peng,Ren; Chen,Binbin; Lin,Yumei

doi:10.3892/or.2017.5956

MicroRNA-381 serves as a prognostic factor and inhibits migration and invasion in non-small cell lung cancer by targeting LRH-1

Retraction in: /10.3892/or.2023.8640

Authors:
- Chunyan Tian
- Jun Li
- Lili Ren
- Ren Peng
- Binbin Chen
- Yumei Lin
View Affiliations

Affiliations: Department of Oncology, Cangnan Hospital Affiliated to Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China, Tumor Department of Hematology, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Department of Oncology, Zhejiang Tumor Hospital, Hangzhou, Zhejiang 310000, P.R. China
Published online on: September 14, 2017 https://doi.org/10.3892/or.2017.5956
Pages: 3071-3077

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Accumulating evidence has demonstrated that aberrant miRNAs were involved in carcinogenesis and tumor progression by regulating oncogenes or tumor suppressor expression. Dysregulation of miR-381 has been reported in different tumors. However, the clinical roles and underlying mechanism in non-small cell lung cancer (NSCLC) remains to be elucidated. We found the expression of miR-381 was significantly downregulated in both NSCLC tissues and cell lines. Clinical analysis revealed the reduced miR-381 was obviously associated with advanced TNM stage and lymph node metastasis. Moreover, we disclosed that miR-381 was a novel independent prognostic marker for predicting 5-year survival of NSCLC patients. The ectopic overexpression of miR-381 inhibited cell migration and invasion in vitro and in vivo. Notably, miR-381 could modulate LRH-1 by directly binding to its 3'-UTR. In clinical samples of NSCLC, miR-381 inversely correlated with LRH-1 expression, which performed positive roles in NSCLC migration and invasion. Alteration of LRH-1 expression at least partially abolished the migration and invasion of miR-381 on NSCLC cells. Here, we identified LRH-1 as a functional target of miR-381 in NSCLC. In conclusion, our data indicated that miR-381 inhibited migration and invasion of NSCLC by targeting LRH-1, and may represent a novel potential therapeutic target and prognostic marker for NSCLC.

View Figures

View References

1	Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Mulshine JL and Sullivan DC: Clinical practice. Lung cancer screening. N Engl J Med. 352:2714–2720. 2005. View Article : Google Scholar : PubMed/NCBI
4	Wang T, Nelson RA, Bogardus A and Grannis FW Jr: Five-year lung cancer survival: Which advanced stage nonsmall cell lung cancer patients attain long-term survival? Cancer. 116:1518–1525. 2010. View Article : Google Scholar : PubMed/NCBI
5	Sax SN, Zu K and Goodman JE: Air pollution and lung cancer in Europe. Lancet Oncol. 14:e439–e440. 2013. View Article : Google Scholar : PubMed/NCBI
6	Taniwaki M, Daigo Y, Ishikawa N, Takano A, Tsunoda T, Yasui W, Inai K, Kohno N and Nakamura Y: Gene expression profiles of small-cell lung cancers: Molecular signatures of lung cancer. Int J Oncol. 29:567–575. 2006.PubMed/NCBI
7	Guo H, Ingolia NT, Weissman JS and Bartel DP: Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
8	Kasinski AL and Slack FJ: Epigenetics and genetics. MicroRNAs en route to the clinic: Progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 11:849–864. 2011. View Article : Google Scholar : PubMed/NCBI
9	Zeng Y, Zhu J, Shen D, Qin H, Lei Z, Li W, Liu Z and Huang JA: MicroRNA-205 targets SMAD4 in non-small cell lung cancer and promotes lung cancer cell growth in vitro and in vivo. Oncotarget. 8:30817–30829. 2017.PubMed/NCBI
10	Liu Z, Dou C, Yao B, Xu M, Ding L, Wang Y, Jia Y, Li Q, Zhang H, Tu K, et al: Methylation-mediated repression of microRNA-129-2 suppresses cell aggressiveness by inhibiting high mobility group box 1 in human hepatocellular carcinoma. Oncotarget. 7:36909–36923. 2016. View Article : Google Scholar : PubMed/NCBI
11	Formosa A, Markert EK, Lena AM, Italiano D, Finazzi-Agro' E, Levine AJ, Bernardini S, Garabadgiu AV, Melino G and Candi E: MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene. 33:5173–5182. 2014. View Article : Google Scholar : PubMed/NCBI
12	Rothschild SI, Tschan MP, Jaggi R, Fey MF, Gugger M and Gautschi O: MicroRNA-381 represses ID1 and is deregulated in lung adenocarcinoma. J Thorac Oncol. 7:1069–1077. 2012. View Article : Google Scholar : PubMed/NCBI
13	Tang H, Liu X, Wang Z, She X, Zeng X, Deng M, Liao Q, Guo X, Wang R, Li X, et al: Interaction of hsa-miR-381 and glioma suppressor LRRC4 is involved in glioma growth. Brain Res. 1390:21–32. 2011. View Article : Google Scholar : PubMed/NCBI
14	Liang Y, Zhao Q, Fan L, Zhang Z, Tan B, Liu Y and Li Y: Down-regulation of MicroRNA-381 promotes cell proliferation and invasion in colon cancer through up-regulation of LRH-1. Biomed Pharmacother. 75:137–141. 2015. View Article : Google Scholar : PubMed/NCBI
15	Zhang Q, Zhao S, Pang X and Chi B: MicroRNA-381 suppresses cell growth and invasion by targeting the liver receptor homolog-1 in hepatocellular carcinoma. Oncol Rep. 35:1831–1840. 2016. View Article : Google Scholar : PubMed/NCBI
16	Xue Y, Xu W, Zhao W, Wang W, Zhang D and Wu P: miR-381 inhibited breast cancer cells proliferation, epithelial-to-mesenchymal transition and metastasis by targeting CXCR4. Biomed Pharmacother. 86:426–433. 2017. View Article : Google Scholar : PubMed/NCBI
17	Xia B, Li H, Yang S, Liu T and Lou G: MiR-381 inhibits epithelial ovarian cancer malignancy via YY1 suppression. Tumour Biol. 37:9157–9167. 2016. View Article : Google Scholar : PubMed/NCBI
18	Cao Q, Liu F, Ji K, Liu N, He Y, Zhang W and Wang L: MicroRNA-381 inhibits the metastasis of gastric cancer by targeting TMEM16A expression. J Exp Clin Cancer Res. 36:292017. View Article : Google Scholar : PubMed/NCBI
19	Li Y, Zhao C, Yu Z, Chen J, She X, Li P, Liu C, Zhang Y, Feng J, Fu H, et al: Low expression of miR-381 is a favorite prognosis factor and enhances the chemosensitivity of osteosarcoma. Oncotarget. 7:68585–68596. 2016. View Article : Google Scholar : PubMed/NCBI
20	Liang HQ, Wang RJ, Diao CF, Li JW, Su JL and Zhang S: The PTTG1-targeting miRNAs miR-329, miR-300, miR-381, and miR-655 inhibit pituitary tumor cell tumorigenesis and are involved in a p53/PTTG1 regulation feedback loop. Oncotarget. 6:29413–29427. 2015. View Article : Google Scholar : PubMed/NCBI
21	Chen T, Ren H, Thakur A, Yang T, Li Y, Zhang S, Wang T and Chen M: miR-382 inhibits tumor progression by targeting SETD8 in non-small cell lung cancer. Biomed Pharmacother. 86:248–253. 2017. View Article : Google Scholar : PubMed/NCBI
22	Liu W, Xiao P, Wu H, Wang L, Kong D and Yu F: MicroRNA-98 plays a suppressive role in non-small cell lung cancer through inhibition of SALL4 protein expression. Oncol Res. Nov 17–2016.(Epub ahead of print).
23	Chen B, Duan L, Yin G, Tan J and Jiang X: miR-381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer cells to 5-FU by up-regulation of Cdc2 activities in 786-O. J Chemother. 25:229–238. 2013. View Article : Google Scholar : PubMed/NCBI
24	Tang H, Wang Z, Liu Q, Liu X, Wu M and Li G: Disturbing miR-182 and −381 inhibits BRD7 transcription and glioma growth by directly targeting LRRC4. PLoS One. 9:e841462014. View Article : Google Scholar : PubMed/NCBI
25	He X, Wei Y, Wang Y, Liu L, Wang W and Li N: MiR-381 functions as a tumor suppressor in colorectal cancer by targeting Twist1. Onco Targets Ther. 9:1231–1239. 2016.PubMed/NCBI
26	Wang Z, Yang J, Xu G, Wang W, Liu C, Yang H, Yu Z, Lei Q, Xiao L, Xiong J, et al: Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors. Oncotarget. 6:3147–3164. 2015. View Article : Google Scholar : PubMed/NCBI
27	Chand AL, Pathirage N, Lazarus K, Chu S, Drummond AE, Fuller PJ and Clyne CD: Liver receptor homologue-1 expression in ovarian epithelial and granulosa cell tumours. Steroids. 78:700–706. 2013. View Article : Google Scholar : PubMed/NCBI
28	Nadolny C and Dong X: Liver receptor homolog-1 (LRH-1): A potential therapeutic target for cancer. Cancer Biol Ther. 16:997–1004. 2015. View Article : Google Scholar : PubMed/NCBI
29	Fayard E, Auwerx J and Schoonjans K: LRH-1: An orphan nuclear receptor involved in development, metabolism and steroidogenesis. Trends Cell Biol. 14:250–260. 2004. View Article : Google Scholar : PubMed/NCBI
30	Jiang W, Tian Y, Jiang S, Liu S, Zhao X and Tian D: MicroRNA-376c suppresses non-small-cell lung cancer cell growth and invasion by targeting LRH-1-mediated Wnt signaling pathway. Biochem Biophys Res Commun. 473:980–986. 2016. View Article : Google Scholar : PubMed/NCBI